<DOC>
	<DOCNO>NCT01051349</DOCNO>
	<brief_summary>Primary Objective ass safety extend treatment Daclizumab High Yield Process ( DAC HYP , BIIB019 ) monotherapy participant relapse remit multiple sclerosis ( RRMS ) . Secondary Objective ass long-term immunogenicity DAC HYP assess durability response DAC HYP prevent multiple sclerosis ( MS ) relapse , slow disability progression , reduce new MS lesion formation study population .</brief_summary>
	<brief_title>Safety Efficacy Extension Study Daclizumab High Yield Process ( DAC HYP ) ( BIIB019 ) Participants Who Have Completed Study 205MS202 ( NCT00870740 ) Treat Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This study provide participant complete Study 205MS202 ( NCT00870740 ) option receive continue open-label Daclizumab High Yield Process ( DAC HYP ) monotherapy evaluate long-term safety , efficacy , immunogenicity DAC HYP monotherapy participant relapse remit multiple sclerosis ( RRMS ) . Approximately 60 100 participant enrol optional open-label , 16-week autoinjector substudy select subset site run concurrently main study , evaluate systemic exposure local tolerability subcutaneous administration DAC HYP autoinjector . The 2013-2014 trivalent influenza vaccine offer eligible participant optional substudy assess effect DAC-HYP treatment immune response vaccination ,</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Main Study Eligibility : Key Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Subjects complete 52 week Study 205MS202 ( NCT00870740 ) compliant 205MS202 protocol opinion Investigator . Women childbearing potential must practice effective contraception study willing able continue contraception 4 month last dose study treatment . Key Subjects significant change medical status previous study would prelude administration Daclizumab High Yield Process ( DAC HYP ) determine Investigator include laboratory test current clinically significant condition , opinion Investigator , would exclude subject 's participation 205MS201 ( NCT00390221 ) 205MS202 ( NCT00870740 ) study . The Investigator must rereview subject 's medical fitness participation must consider disease would preclude treatment . Any subject permanently discontinue study treatment Study 205MS202 ( NCT00870740 ) due adverse event . Current enrollment investigational drug study Study 205MS202 ( NCT00870740 ) . Ongoing treatment approve experimental diseasemodifying treatment multiple sclerosis . For subject currently take valproic acid , carbamazepine , lamotrigine , phenytoin : Subjects treat agent few 6 month prior study entry exclude study participation unless discontinue agent ( ) prior study entry . Subjects treat 2 agent 6 month prior study entry exclude study participation unless reduce â‰¤1 agent prior study entry . Subjects dose escalation one agent within 6 month prior study entry exclude study participation unless revert previous dose use least 6 month prior study entry unless discontinue agent prior study entry Subjects currently receive treatment isoniazid , propylthiouracil , nimesulide time study entry able discontinue agent change alternative medication allow protocol . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>